Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 2,764 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Cognition, BDNF
Interventions: d-beta-hydroxybutrate, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Long COVID, Brain Fog, Cognitive Impairment, Cognitive Dysfunction, Post-Acute COVID-19 Syndrome
Interventions: Processing Speed Training, In-lab Instrumental Activities of Daily Living Training, In-lab Brain Health Training, Transfer Package, Follow Up Phone Calls, Vocational Rehabilitation, Peer Mentoring, Reaction Time Training, Trans-auricular Vagus Nerve Stimulation: High Intensity, Trans-auricular Vagus Nerve Stimulation: Low Intensity; Behavioral · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infections
Interventions: PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV); Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions: Oxycodone CR (standard pain medication), JNJ-42160443, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 36
States / cities: Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more

Conditions: ALS
Interventions: [11C]-PBR28; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Dependence
Interventions: Prazosin Tablet, Placebo Tablet; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Retinoblastoma, Retinal Neoplasm
Interventions: Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF; Procedure · Drug · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Alcohol Abuse
Interventions: Brief Advice, NIAAA Clinician's Guide, Motivational Interviewing (MI); Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Seriously Ill Hospitalized Patients
Interventions: Default Order, Accountable Justification, Standardized Usual Care; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 78,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Pasadena, California • Livonia, Michigan

Conditions: Obesity
Interventions: Moderate intensity weight loss, High intensity medical weight loss; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: MIJ821, Placebo, Ketamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more

Conditions: Child, Overweight, Sedentary Lifestyle
Interventions: High Autonomy, Low Autonomy; Other
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 8 Years to 12 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Obesity, Prediabetic State, Type 2 Diabetes
Interventions: Health Education and Coaching Strategy, Dietary consult; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 16
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Rheumatoid Arthritis
Interventions: LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 13
States / cities: Gainesville, Florida • Orange Park, Florida • Orlando, Florida + 10 more

Conditions: Huntington Disease, Healthy
Interventions: ActiGraph LEAP, Axivity AX6; Device
Lead sponsor: University of Rochester; Other
Eligibility: 25 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Focal Seizure, Epilepsy, Focal Epilepsy
Interventions: RAP-219, Placebo; Drug · Other
Lead sponsor: Rapport Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Birmingham, Alabama • Palmdale, California • San Francisco, California + 14 more

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Healthy
Interventions: kTMP, Sham kTMP; Device
Lead sponsor: Magnetic Tides; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: El Cerrito, California

Conditions: Neuroendocrine Tumors
Interventions: fosbretabulin; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more

Conditions: Weight Loss
Interventions: Protein supplementation, Diet counseling and group education lessons; Dietary Supplement · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ankle Sprain
Interventions: High velocity, low amplitude stretch, Slow, mobilization stretch, Passive Positioning; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Brain Care Score, Exercise, Hypertension, BMI
Interventions: Exercise Intervention to improve overall Brain Health; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 35 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Myelodysplastic Syndrome
Interventions: Vosaroxin; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism

Long COVID Brain Fog: Cognitive Rehabilitation Trial

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Multimodal Imaging Outcome Measures for ALS (Image ALS)

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

Mentored Research on Improving Alcohol Brief Interventions in Medical Settings

Comparing Optimized Models of Primary And Specialist Services for Palliative Care

Impact of Weight Loss on Physical Function

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Active Games: Increasing the Attractiveness of Active Video Game Play for Youth

Lifestyle-Related Health Outcomes in Prediabetes and Diabetes

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Parameter Space of kTMP

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Measuring Eating, Activity and Strength: Understanding the Response -Using Protein

Ankle Sprains and Corticospinal Excitability

An Exercise Intervention to Improve Overall Brain Health

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy